Evidence map›Paper›PMID 32445364›Full record

ArticleThe journal of applied laboratory medicine2020

Light Forge: A Microfluidic DNA Melting-based Tuberculosis Test.

Ian M Mbano, Tawanda Mandizvo, Jerome Rogich, Tafara T R Kunota, Jared S Mackenzie, Manormoney Pillay, Frederick K Balagaddé

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of applied laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ian M MbanoAfrica Health Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa.
Tawanda MandizvoAfrica Health Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa.
Jerome RogichUniversity of Massachusetts Medical School, Worcester, MA.
Tafara T R KunotaAfrica Health Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa.
Jared S MackenzieAfrica Health Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa.
Manormoney PillayMedical Microbiology, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Frederick K BalagaddéAfrica Health Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa.
University of KwaZulu-Natal · ZAAfrica Health Research Institute · ZAUniversity of Massachusetts Chan Medical School · US

Funding

Howard Hughes Medical InstituteWellcome TrustWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

backgroundThere is a well-documented lack of rapid, low-cost tuberculosis (TB) drug resistance diagnostics in low-income settings across the globe. It is these areas that are plagued with a disproportionately high disease burden and in greatest need of these diagnostics.

methodsIn this study, we compared the performance of Light Forge, a microfluidic high-resolution melting analysis (HRMA) prototype for rapid low-cost detection of TB drug resistance with a commercial HRMA device, a predictive "nearest-neighbor" thermodynamic model, DNA sequencing, and phenotypic drug susceptibility testing (DST). The initial development and assessment of the Light Forge assay was performed with 7 phenotypically drug resistant strains of Mycobacterium tuberculosis (M.tb) that had their rpoB gene subsequently sequenced to confirm resistance to Rifampin. These isolates of M.tb were then compared against a drug-susceptible standard, H37Rv. Seven strains of M.tb were isolated from clinical specimens and individually analyzed to characterize the unique melting profile of each strain.

resultsLight Forge was able to detect drug-resistance linked mutations with 100% concordance to the sequencing, phenotypic DST and the "nearest neighbor" thermodynamic model. Researchers were then blinded to the resistance profile of the seven M.tb strains. In this experiment, Light Forge correctly classified 7 out of 9 strains as either drug resistant or drug susceptible.

conclusionsLight Forge represents a promising prototype for a fast, low-cost diagnostic alternative for detection of drug resistant strains of TB in resource constrained settings.

Indexed as

Molecular Diagnostic TechniquesAntitubercular AgentsBacterial ProteinsDNA, BacterialHumansMicrobial Sensitivity TestsMicrofluidicsMycobacterium tuberculosisNucleic Acid DenaturationPolymerase Chain ReactionReal-Time Polymerase Chain ReactionReproducibility of ResultsSequence Analysis, DNAThermodynamicsTuberculosisAntitubercular AgentsBacterial ProteinsDNA, BacterialDrug resistanceHigh-resolution melting analysisMolecular diagnosticsMycobacterium tuberculosisReal-time PCR

Identifiers

PMID32445364
PMCPMC7192548
OpenAlexW3022133419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.